Granted Patent B2

US 12,661,408 · App. 19/238,194 · Granted Jun 23, 2026

Inventor: Herriot Tabuteau (New York, NY)

Assignee: ANTECIP BIOVENTURES II LLC

A61K47/542A61K9/2009A61K9/2013A61K9/2054A61K9/209A61K31/137A61K31/198A61K31/485

Abstract

Claims (19)

1 . A method of treating depression in a human being in need thereof with a dosage form comprising dextromethorphan, bupropion, and cysteine, comprising orally administering the dosage form comprising the dextromethorphan, the bupropion, and the cysteine, wherein the dosage form comprises about 45 mg of dextromethorphan hydrobromide, about 105 mg of bupropion hydrochloride, and a cysteine in a salt form, wherein the dosage form has a molar ratio of the bupropion to the cysteine that is about 0.5:1 to about 1.1:1, wherein the cysteine salt is in an equivalent amount of about 40 mg to about 50 mg of the neutral form of cysteine, wherein bupropion and dextromethorphan are the only therapeutic active agents in the dosage form, wherein the dosage form is a bilayer dosage form, and wherein the bupropion and the cysteine are in a first layer and the dextromethorphan is in a second layer.

2 . The method of claim 1 , wherein the dosage form has a molar ratio of the bupropion to the cysteine that is about 0.7:1 to about 1.1:1.

3 . The method of claim 1 , wherein the molar ratio of the bupropion to the cysteine is about 1:1.

4 . The method of claim 1 , wherein the dosage form further comprises an extended release polymer.

5 . The method of claim 4 , wherein the extended release polymer is an acrylate polymer or copolymer, a methylcellulose, or a combination thereof.

6 . The method of claim 1 , wherein the dosage form is in the form of a capsule, pill, or tablet.

7 . The method of claim 1 , wherein the dosage form further comprises a filler.

8 . The method of claim 7 , wherein the filler is microcrystalline cellulose.

9 . The method of claim 1 , wherein the dosage form further comprises a lubricant.

10 . The method of claim 9 , wherein the lubricant is magnesium stearate.

11 . The method of claim 1 , wherein the cysteine is L-cysteine hydrochloride monohydrate.

12 . The method of claim 1 , wherein the dosage form comprises a molecular complex of bupropion and cysteine.

13 . The method of claim 12 , wherein the bupropion in the dosage form is more stable than the bupropion alone.

14 . The method of claim 1 , wherein the bupropion in the dosage form is more stable than the bupropion alone.

15 . The method of claim 1 , wherein the dextromethorphan is in an immediate-release formulation.

16 . The method of claim 15 , wherein the bupropion is in an extended-release formulation.

17 . The method of claim 12 , wherein the molar ratio of the bupropion to the cysteine in the molecular complex is about 1:1.

18 . The method of claim 6 , wherein the dosage form is a tablet.

19 . The method of claim 18 , wherein the tablet further comprises carbomer homopolymer, colloidal silicon dioxide, crospovidone, glyceryl monocaprylocaprate, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, red iron oxide, sodium lauryl sulfate, stearic acid, talc, titanium dioxide, yellow iron oxide, or a combination thereof.

Assignments (2)

Continuity (6)

References Cited (400)